REFERENCES
1. Alshabeeb MA, Deneer VHM, Khan A, Asselbergs FW. Use of
Pharmacogenetic Drugs by the Dutch Population. Front Genet 2019; 10:
567.
2. Chang CJ, Chen CB, Hung SI, Ji C, Chung WH. Pharmacogenetic Testing
for Prevention of Severe Cutaneous Adverse Drug Reactions. Front
Pharmacol 2020; 11: 969.
3. Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein
CM, Moyer AM, Evans WE, Klein TE, Antillon-Klussmann FG, Caudle KE, Kato
M, Yeoh AEJ, Schmiegelow K, Yang JJ. Clinical Pharmacogenetics
Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT
and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019; 105:
1095-105.
4. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ,
van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW,
Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ,
de Boer A, Boersma C, Deneer VHM, Ten Berg JM. A Genotype-Guided
Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med 2019;
381: 1621-31.
5. Drogemoller BI, Wright GEB, Shih J, Monzon JG, Gelmon KA, Ross CJD,
Amstutz U, Carleton BC, Group CCR. CYP2D6 as a treatment decision aid
for ER-positive non-metastatic breast cancer patients: a systematic
review with accompanying clinical practice guidelines. Breast Cancer Res
Treat 2019; 173: 521-32.
6. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M,
Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk
A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical
Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6
and Tamoxifen Therapy. Clin Pharmacol Ther 2018; 103: 770-77.
7. van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukic MM.
Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far
Have We Got and Where Are We Going? Front Psychiatry 2020; 11: 94.
8. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio
IT, Zackrisson S, Senkus E, clinicalguidelines@esmo.org EGCEa. Early
breast cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-updagger. Ann Oncol 2019; 30: 1194-220.
9. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE,
Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van
Poznak C, Bast RC, Hayes DF, American Society of Clinical O. Use of
Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women
With Early-Stage Invasive Breast Cancer: American Society of Clinical
Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34: 1134-50.
10. Park SK, Thigpen J, Lee IJ. Coverage of pharmacogenetic tests by
private health insurance companies. J Am Pharm Assoc (2003) 2020; 60:
352-56 e3.
11. Somogyi AA, Phillips E. Genomic testing as a tool to optimise drug
therapy. Aust Prescr 2017; 40: 101-04.
12. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care
physicians’ knowledge of and experience with pharmacogenetic testing.
Clin Genet 2012; 82: 388-94.
13. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD,
Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV,
Hoffman JM. Standardizing terms for clinical pharmacogenetic test
results: consensus terms from the Clinical Pharmacogenetics
Implementation Consortium (CPIC). Genet Med 2017; 19: 215-23.
14. Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo ME,
Delgado A, de Andres F, Lopez-Lopez M, Penas-Lledo E, A LL. Interethnic
variation of CYP2C19 alleles, ’predicted’ phenotypes and ’measured’
metabolic phenotypes across world populations. Pharmacogenomics J 2016;
16: 113-23.
15. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK,
Peterson LM, Veldhuizen TL, Fadra N, Peterson SE, Lagerstedt SA, Train
LJ, Baudhuin LM, Klee EW, Ferber MJ, Bielinski SJ, Caraballo PJ,
Weinshilboum RM, Black JL, 3rd. Preemptive Pharmacogenomic Testing for
Precision Medicine: A Comprehensive Analysis of Five Actionable
Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a
Customized CYP2D6 Genotyping Cascade. J Mol Diagn 2016; 18: 438-45.
16. Naranjo MG, Rodrigues-Soares F, Penas-Lledo EM, Tarazona-Santos E,
Farinas H, Rodeiro I, Teran E, Grazina M, Moya GE, Lopez-Lopez M,
Sarmiento AP, Calzadilla LR, Ramirez-Roa R, Ortiz-Lopez R,
Estevez-Carrizo FE, Sosa-Macias M, Barrantes R, A LL, Pharmacogenetics
CE-CotI-ANo, Pharmacogenomics R. Interethnic Variability in CYP2D6,
CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among
6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on
Population Pharmacogenomics. OMICS 2018; 22: 575-88.
17. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA,
Cowan JD, Xu H, Ramirez AH, Crawford DC, Ritchie MD, Peterson JF, Masys
DR, Wilke RA, Roden DM. Optimizing drug outcomes through
pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther
2012; 92: 235-42.
18. Russmann S, Rahmany A, Niedrig D, Hatz K, Ludin K, Burden A,
Englberger L, Backhaus R, Serra A, Bechir M. Implementation and
Management Outcomes of Pharmacogenetic CYP2C19 Testing for Clopidogrel
Therapy in Clinical Practice. Eur J Clin Pharmacol 2020; in press.
19. Moliterno DJ, Smyth SS, Abdel-Latif A. CYP2C19 Genotyping to Guide
Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size
Rarely Fits All. JAMA 2020; 324: 747-49.
20. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M,
Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu
YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF,
Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect
of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional
Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary
Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 2020; 324:
761-71.
21. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of
drug-induced liver injury. Hepatology 2010; 52: 748-61.
22. Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P.
Genetic polymorphisms related to efficacy and overuse of triptans in
chronic migraine. J Headache Pain 2010; 11: 431-5.
23. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J,
Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S,
Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, Team P-S. HLA-B*5701
screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:
568-79.
24. Phillips EJ, Sukasem C, Whirl-Carrillo M, Muller DJ, Dunnenberger
HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Jr.,
Mushiroda T, Klein T, Gammal RS, Pirmohamed M. Clinical Pharmacogenetics
Implementation Consortium Guideline for HLA Genotype and Use of
Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther 2018;
103: 574-81.